StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
September 3, 2026 6:57 AM
H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Neutral rating on Summit Therapeutics plc (NASDAQ: SMMT).The analyst commented: "HARMONi-2’s interim ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
